Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) PT Raised to $206 at BMO Capital

August 8, 2018 7:00 AM
BMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $206.00 (from $201.00) while maintaining a Outperform rating.Analsyt ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles